Researchers in the U.K. have successfully generated small antibodies, or nanobodies, that can target toxic aggregates of misfolded proteins, including alpha-synuclein, a hallmark of Parkinson’s disease. The antibodies, which were generated using a new antibody-discovery platform, can help understand how protein clumps, or aggregates are formed, and identify specific…
Swedish-based Smartcella has entered an agreement with a research team from the Karolinska Institute for the exclusive rights to advance a cell replacement therapy for Parkinson’s disease into clinical development and commercialization. The Karolinska Institute team in Sweden, led by Johan Ericson, PhD, a professor of developmental biology, has…
Kenai Therapeutics is setting up research and laboratory facilities at Lilly Gateway Labs in San Diego, to help advance RNDP-001, its investigational dopaminergic neuron replacement therapy for Parkinson’s disease. By joining Gateway Labs, Kenai, formerly Ryne Biotechnologies, will have access to state-of-the-art facilities, along with resources and…
A research initiative aims to create a mobile app using artificial intelligence (AI) to make strength training at home more effective for people with Parkinson’s disease and other neurological conditions. The technology is being developed by Myworkout AS, in collaboration with the Norwegian University of Science and Technology…
Gardenin A, a compound found in a common South Asian shrub, lessened both cognitive and motor symptoms of Parkinson’s in a mouse model of the disease, according to a study. The compound reduced the loss of dopaminergic neurons — nerve cells that are gradually lost in Parkinson’s— and decreased…
An Australian company announced that it is working on a direct, nose-to-brain way of delivering dopamine that might more effectively treat Parkinson’s disease. PreveCeutical anticipates that this approach, based on what it calls a sol-gel solution that turns into a gel once in contact with mucosa tissue…
The Parkinson’s Foundation hosted a series of events last year that aimed to recognize the unique needs and experiences of Black and African American people with Parkinson’s disease and empower these patients to participate in research. As part of an initiative called Parkinson’s Journey in Color: Advancing Research…
As people age, the immune system ages with them, becoming more sluggish and ineffective — a change that could contribute to Parkinson’s disease, Rebecca Wallings, a 2024 Parkinson’s Foundation Launch Award grant recipient, suggests. “As you age … your immune cells can become exhausted … slow, sluggish, and…
Ncardia has launched a human-derived microglia cell model, called Ncyte Microglia, that the company says may help advance research in Parkinson’s disease and other neurodegenerative conditions — and which may be a tool in the development of new therapies. Microglia are resident immune cells in the brain that…
The European Medicines Agency (EMA), which evaluates the safety and efficacy of new drugs in the European Union, has waived a requirement that would have had Irlab Therapeutics conducting clinical trials testing mesdopetam — its therapy candidate for levodopa-induced dyskinesia, or uncontrolled, involuntary movements common in Parkinson’s disease…
Get regular updates to your inbox.
